Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18893492 | 0.86 | HTT (0.44) | ALDH1A1HTTRAPGEF4MAPTCYP3A4 | |
| SCHEMBL1800645 | 0.83 | KMT2A (0.50) | ALDH1A1HTTMAPTCYP3A4RECQL | |
| SCHEMBL29659123 | 0.83 | MAPT (0.46) | ALDH1A1HTTRAPGEF4MAPTCYP3A4 | |
| SCHEMBL631579 | 0.83 | MAPT (0.46) | ALDH1A1HTTRAPGEF4MAPTCYP3A4 | |
| SCHEMBL15827436 | 0.82 | ALDH1A1 (0.49) | ALDH1A1HTTRAPGEF4MAPTGAA | |
| SCHEMBL1803111 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HTTMAPTCYP3A4RECQL | |
| SCHEMBL30536438 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HTTMAPTCYP3A4RECQL | |
| SCHEMBL20714856 | 0.80 | MAPT (0.43) | ALDH1A1HTTRAPGEF4MAPTCYP3A4 | |
| SCHEMBL5003764 | 0.80 | ABL1 (0.54) | ALDH1A1HTTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16966569 | 0.78 | ABL1 (0.44) | ALDH1A1MAPTCYP3A4RECQLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144793-A1 | POL THETA INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023138362-A1 | WEE1 INHIBITOR, PREPARATION THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2023-07-27 | — | — | WO | disclosed |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-7928135-B2 | Benzene, pyridine, and pyridazine derivatives | SERENEX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-17 | — | — | US | disclosed |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | SERENEX, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7846931-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-02-19 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1366020-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072536-A1 | UREA DERIVATIVES HAVING VANILLOID RECEPTOR (VR1) ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-09-19 | — | — | WO | disclosed |
| US-4912258-A | A 4-fluoroaniline compound | BOEHRINGER MANNHEIM GMBH (DE) | 1990-03-27 | — | — | US | disclosed |
| EP-0161482-B1 | FLUORINATED ANILINE DERIVATIVES AND THEIR USE | Roche Diagnostics GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0161482-A1 | Fluorinated aniline derivatives and their use | Roche Diagnostics GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039838-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ALDH1A1 3252/4885HTT 1673/4885RAPGEF4 677/4885 |
| US-10590076-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | ALDH1A1 3850/4885HTT 2894/4885RAPGEF4 1758/4885 |
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | ALDH1A1 3850/4885HTT 2894/4885RAPGEF4 1758/4885 |
| US-20090163493-A9 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | ALDH1A1 2373/4885HTT 545/4885RAPGEF4 2442/4885 |
| US-20040082661-A1 | Urea derivatives having vanilloid receptor (vr1) antagonist activity | UTS2R, TRPV1, VRK1 | ALDH1A1 1337/4885HTT 3672/4885RAPGEF4 1636/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | ALDH1A1 2373/4885HTT 545/4885RAPGEF4 2442/4885 |
| US-20110034529-A1 | BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES | CDK4, P2RX4, MKI67 | ALDH1A1 1049/4885HTT 3158/4885RAPGEF4 3156/4885 |
| US-20090048244-A1 | PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS | ERBB2, ERBB4, ERBB3 | ALDH1A1 3252/4885HTT 1673/4885RAPGEF4 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.